NEW YORK (TheStreet) -- CHANGE IN RATINGSBoston Scientific ( BSX) downgraded at Goldman from Neutral to Sell. Stock also added to the Conviction list, as the company could lose market share. Clorox ( CLX) upgraded at Barclays to Overweight from Equal Weight as the company is experiencing top line momentum. Price target jumped to $71 from $67. 2010 and 2011 EPS estimates set at $4.23 and $4.73, respectively. Coventry Health ( CVH) upgraded at Goldman from Sell to Neutral. Valuation call. Onyx Pharmaceuticals ( ONXX) upgraded at Goldman from Neutral to Buy. $37 price target. Company has an attractive pipeline, and good be an attractive acquisition target. Parexel ( PRXL) upgraded at Goldman to Buy. Company can deliver above-average earnings growth. Psychiatric Solutions ( PSYS) downgraded at Wells from Outperform to Market Perform. Stock is already pricing in a potential buyout. Starbucks ( SBUX) upgraded at UBS from Neutral to Buy. $29 price target. Estimates also raised, given the company's strong sales and earnings momentum. Universal American ( UAM) downgraded at Goldman from Neutral to Sell. Stock was also added to the Conviction list, based on valuation. Pharmasset ( VRUS) initiated at Citi with a Buy rating and $34 price target. RG7128 should become a major drug in the hepatitis C market. Western Union ( WU) downgraded at William Blair from Outperform to Market Perform. Valuation call, as the stock lacks catalysts. Wyndham Worldwide ( WYN) downgraded at Goldman from Buy to Neutral. Valuation call, based on a $26 price target.
Ford ( F) estimates, target increased at UBS. Shares of F now seen reaching $15. Estimates also upped, as the company is likely to gain market share from other U.S. makers. Buy rating. Kimberly-Clark ( KMB) added to Conviction Sell List at Goldman. Estimates also lowered, because of rising pulp prices. $57 price target. Kansas City Southern ( KSU) numbers increased at Goldman. KSU estimates were boosted through 2012. Company is seeing higher cross-border traffic with Mexico. Neutral rating and new $40 price target. Limited Brands ( LTD) estimates higher at Credit Suisse. LTD 2011 and 2012 EPS estimates boosted to $1.64 and $1.95, respectively. The company announced a special $1/share dividend and new $200 million buyback plan. Maintain Neutral rating and $20 price target. Limited Brands ( LTD) numbers boosted at Goldman. Shares of LTD now seen reaching $24. Estimates also increased, given the company's buyback program. Neutral rating. Microchip ( MCHP) estimates raised at UBS through 2011. Company is seeing solid bookings and shipments. Neutral rating and $28 price target. Massey Energy ( MEE) price target raised at Barclays to $56 from $56. Equal Weight rating. 2010 and 2011 EPS estimates set at $1.25 and $2.15, respectively. Priceline.com ( PCLN) estimates raised at Goldman. PCLN estimates were increased through 2012. Numbers updated for recent convertible offering. Buy rating. Research in Motion ( RIMM) estimate tweaked at Barclays. RIMM 2011 EPS estimates lifted 5 cents to $5.08, 2010 held at $4.40. Maintain Overweight rating and $85 price target. Swift Energy ( SFY) numbers increased at UBS through 2011. Company can deliver strong production growth and reserve replacement. Buy rating and new $38 price target. St. Jude ( STJ) removed from Conviction Sell List at Goldman Sachs. Company can gain market share, though pricing pressures remain. Teva Pharma ( TEVA) cut from Conviction Buy List at Goldman Sachs. Valuation call. UnitedHealth ( UNH) cut from Conviction Buy List at Goldman Sachs. Company has continued exposure to Medicare Advantage. Valley National ( VLY) estimates raised at UBS. VLY estimates were boosted through 2011. FDIC acquisitions should add to earnings. Sell rating and $11 price target.